Oxabolone cipionate
Identification
- Generic Name
- Oxabolone cipionate
- DrugBank Accession Number
- DB13185
- Background
Oxabolone cipionate is the C17β cypionate ester and a prodrug of Oxabolone. A synthetic anabolic-androgenic (AAS) steroid, it is a derivative of 19-nortestosterone (nandrolone). It is considered as a performance enhancing drug thus is prohibited from use in sports.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 414.586
Monoisotopic: 414.277009704 - Chemical Formula
- C26H38O4
- Synonyms
- 4-hydroxy-19-nortestosterone 17β-cypionate
- Cipionate d'oxabolone
- Cipionato de oxabolona
- Oxabolone 17-cyclopentanepropionate
- Oxabolone cipionate
- Oxabolone cypionate
- Oxaboloni cipionas
- External IDs
- FI 5852
- FI-5852
Pharmacology
- Indication
Used as a performance enhancing drug illicitly in athletes.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Androgenic effects include enhanced secondary sexual characteristics.
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
The prodrug oxabolone cipionate is converted to oxabolone. Oxabolone is then metabolized into 4-Hydroxyestr-4-en-3,17-dione (M2) which is the most abundant metabolite via oxidation of the 17-hydroxyl group. 4-Hydroxyestran-3,17-dione (M1) is formed by reduction of the A ring double bond along with the oxidation of the 17-hydroxyl group. Three isomeric compounds exist as another metabolite, as the 3α,4-dihydroxy-5α-estran-17-one, 3α,4-dihydroxy-5β-estran-17-one, and 3β,4-dihydroxy-5α-estran-17-one 2.
Hover over products below to view reaction partners
- Route of elimination
The metabolites and unchanged form of oxabolone can be detected in the urine 2.
- Half-life
Not Available
- Clearance
The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration 2.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Oxabolone cipionate which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- Not Available
Categories
- ATC Codes
- A14AB03 — Oxabolone cipionate
- Drug Categories
- Alimentary Tract and Metabolism
- Anabolic Agents for Systemic Use
- Anabolic Steroids
- Drugs that are Mainly Renally Excreted
- Estradiol Congeners
- Estranes
- Estren Derivatives
- Estrenes
- Fused-Ring Compounds
- Gonadal Hormones
- Gonadal Steroid Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Steroids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid esters
- Direct Parent
- Steroid esters
- Alternative Parents
- Estrogens and derivatives / Hydroxysteroids / 3-oxo delta-4-steroids / Delta-4-steroids / Cyclohexenones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Enols / Organic oxides / Hydrocarbon derivatives
- Substituents
- 3-oxo-delta-4-steroid / 3-oxosteroid / 4-hydroxysteroid / Aliphatic homopolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Cyclohexenone / Delta-4-steroid
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5RXY50Q01N
- CAS number
- 1254-35-9
- InChI Key
- KHKDIUPVDIEHAH-KXLSUQFWSA-N
- InChI
- InChI=1S/C26H38O4/c1-26-15-14-18-17-9-11-22(27)25(29)20(17)8-7-19(18)21(26)10-12-23(26)30-24(28)13-6-16-4-2-3-5-16/h16-19,21,23,29H,2-15H2,1H3/t17-,18-,19-,21+,23+,26+/m1/s1
- IUPAC Name
- (1S,2R,10R,11S,14S,15S)-6-hydroxy-15-methyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl 3-cyclopentylpropanoate
- SMILES
- [H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(O)C(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1
References
- General References
- Kicman AT: Pharmacology of anabolic steroids. Br J Pharmacol. 2008 Jun;154(3):502-21. doi: 10.1038/bjp.2008.165. [Article]
- Barbarulo MV, Buiarelli F, Ciardi M, Giarrusso A, Rosati F, Cartoni GP: Capillary GC-MS investigation of the metabolism and excretion of oxabolone in man Journal of Separation Science. 1995 Nov 1;18(11):705–708. [Article]
- Hartgens F, Kuipers H: Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54. [Article]
- Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH: Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004 Jun;38(3):253-9. [Article]
- External Links
- PubChem Compound
- 68952
- PubChem Substance
- 347829285
- ChemSpider
- 62175
- ChEBI
- 31940
- ChEMBL
- CHEMBL2105318
- ZINC
- ZINC000026892649
- Wikipedia
- Oxabolone_cipionate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00377 mg/mL ALOGPS logP 4.43 ALOGPS logP 5.29 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 9.23 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 63.6 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 116.85 m3·mol-1 Chemaxon Polarizability 48.9 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0100900000-3b6d2dea50976712ccbe Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00xr-0090500000-73fbc744714a63b95003 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-1433900000-6cc2a514d7b0b447fb14 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-3593800000-fbedabda6a9dc3352e1b Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-03dl-7518900000-6a7e14eb4cc2b455048b Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-1791100000-29af4da0b8d027e56c7e Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 220.9254653 predictedDarkChem Lite v0.1.0 [M-H]- 203.58447 predictedDeepCCS 1.0 (2019) [M+H]+ 222.0242653 predictedDarkChem Lite v0.1.0 [M+H]+ 205.47989 predictedDeepCCS 1.0 (2019) [M+Na]+ 221.4524653 predictedDarkChem Lite v0.1.0 [M+Na]+ 211.52594 predictedDeepCCS 1.0 (2019)
Drug created at June 15, 2017 22:50 / Updated at February 21, 2021 18:54